C-Path and CHDI launch consortium to accelerate development of Huntington's therapies

(Critical Path Institute (C-Path)) C-Path and CHDI announce the launch of the Huntington's Disease Regulatory Science Consortium (HD-RSC) to advance innovation in regulatory science methods, drug development tools, and clearer regulatory pathways to accelerate the approval of HD therapeutics. HD-RSC will facilitate clinical data sharing and standardization, and the development of modeling tools, biomarkers, and clinical outcome assessments to help de-risk the drug-development pathway, potentially expedite regulatory review, and thereby incentivize drug developers to enter the HD sphere.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news